Hyporesponsiveness following booster immunization with bacterial polysaccharides is caused by apoptosis of memory B cells

Journal of Infectious Diseases

Volumn 205, Issue 3, 2012, Pages 422-430

  Brynjolfsson, Siggeir F ^a,b   Henneken, Maren ^a   Bjarnarson, Stefania P ^a,b   Mori, Elena ^c   Del Giudice, Giuseppe ^c   Jonsdottir, Ingileif ^a,b,d  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^d DECODE GENETICS   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL POLYSACCHARIDE; BROXURIDINE; CPG 1826; CPG 2006; MENINGOCOCCUS SEROTYPE C CRM197 CONJUGATE VACCINE; MENINGOCOCCUS SEROTYPE C POLYSACCHARIDE CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFECT; DRUG RESPONSE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; MEMORY CELL; MENINGOCOCCOSIS; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEROTYPE; SPLEEN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANIMALS, NEWBORN; ANNEXIN A5; ANTIGENS, CD45; APOPTOSIS; B-LYMPHOCYTES; BONE MARROW; FEMALE; FLOW CYTOMETRY; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; MENINGOCOCCAL VACCINES; MICE; OLIGODEOXYRIBONUCLEOTIDES; POLYSACCHARIDES, BACTERIAL; SPLEEN; SYNDECAN-1; VACCINES, CONJUGATE;

EID: 84855873411     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir750     Document Type: Article

References (35)

1. World Health Organization (WHO). Meningitis in Chad, Niger, and Nigeria: 2009 epidemic season. Wkly Epidemiol Rec 2010;85:47-63.
2. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007;369:2196-210. (Pubitemid 46977462)
3. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 1975;56:1536-47.
4. Leach A, Twumasi PA, Kumah S, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997;175:200-4. (Pubitemid 27020849)
5. MacLennan J, Obaro S, Deeks J, et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J Infect Dis 2001;183:97-104. (Pubitemid 32043046)
6. MacLennan J, Obaro S, Deeks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 1999;17:3086-93. (Pubitemid 29366989)
7. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998;280:1685-9. (Pubitemid 28532992)
8. Borrow R, Goldblatt D, Andrews N, Richmond P, Southern J, Miller E. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis 2001;184:377-80. (Pubitemid 32662189)
9. Borrow R, Southern J, Andrews N, et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 2001;19:3043-50. (Pubitemid 32324031)
10. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000;181:761-4. (Pubitemid 30131856)
11. Southern J, Deane S, Ashton L, et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 2004;11:1100-4. (Pubitemid 39540851)
12. Borrow R, Joseph H, Andrews N, et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine 2000;19:1129-32. (Pubitemid 32008278)
13. Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 2011;10:307-22.
14. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009;9:213-20.
15. Granoff DM, Pollard AJ. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 2007;26:716-22. (Pubitemid 47424642)
16. Dunn-Walters DK, Ademokun AA. B cell repertoire and ageing. Curr Opin Immunol 2010;22:514-20.
17. Del Giudice G. Vaccination strategies: an overview. Vaccine 2003;21(Suppl 2): S83-8. (Pubitemid 36588653)
18. Kovarik J, Bozzotti P, Love-Homan L, et al. CpG oligonucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol 1999;162:1611-17. (Pubitemid 29307036)
19. MacDonald NE, Halperin SA, Law BJ, Danzig LE, Granoff DM. Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine? JAMA 2000;283:1826-7. (Pubitemid 30207616)
20. Brynjolfsson SF, Bjarnarson SP, Mori E, Del Giudice G, Jonsdottir I. Neonatal immune response and serum bactericidal activity induced by a meningococcal conjugate vaccine is enhanced by LT-K63 and CpG2006. Vaccine 2008;26:4557-62.
21. Capolunghi F, Cascioli S, Giorda E, et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol 2008;180:800-8.
22. Jokhdar H, Borrow R, Sultan A, et al. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol 2004;11:83-8. (Pubitemid 38090656)
23. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998;178:870-4. (Pubitemid 28397241)
24. Choo S, Zuckerman J, Goilav C, Hatzmann E, Everard J, Finn A. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A+C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine 2000;18:2686-92. (Pubitemid 30211576)
25. Belnoue E, Pihlgren M, McGaha TL, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008;111:2755-64.
26. Russell FM, Carapetis JR, Balloch A, et al. Hyporesponsiveness to rechallenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine 2010;28:3341-9.
27. Sigurdardottir ST, Center KJ, Davidsdottir K, et al. Characterization of the immune response to pneumococcal conjugate vaccine after 23-valent polysaccharide vaccine (ppv23) in children. In: The 29th Annual Meeting of the European Society for Paediatrics Infectious Diseases. The Hauge, the Netherlands: ESPID, 2011.
28. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243-8. (Pubitemid 29058113)
29. Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003;22:96-103. (Pubitemid 37357156)
30. Jackson LA, Neuzil KM, Nahm MH, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007;25:4029-37. (Pubitemid 46616998)
31. Vakevainen M, Soininen A, Lucero M, et al. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J Pediatr 2010;157:778-83 e1.
32. Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010;201:1570-9.
33. Vu DM, de Boer AW, Danzig L, et al. Priming for immunologic memory in adults by meningococcal group C conjugate vaccination. Clin Vaccine Immunol 2006;13:605-10. (Pubitemid 44032504)
34. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54:1-21.
35. Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis 2010;50(Suppl 2): S45-53.